Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)

Abstract Background The squamous cell carcinoma of the anus (SCCA) is a rare disease, but its incidence is markedly increasing. About 15% of patients are diagnosed at metastatic stage, and more than 20% with a localized disease treated by chemoradiotherapy (CRT) will recur. In advanced SCCA, cisplat...

Full description

Bibliographic Details
Main Authors: Stefano Kim, Marine Jary, Thierry André, Véronique Vendrely, Bruno Buecher, Eric François, François-Clément Bidard, Sarah Dumont, Emmanuelle Samalin, Didier Peiffert, Simon Pernot, Nabil Baba-Hamed, Farid El Hajbi, Olivier Bouché, Jérôme Desrame, Aurélie Parzy, Mustapha Zoubir, Christophe Louvet, Jean-Baptiste Bachet, Thierry Nguyen, Meher Ben Abdelghani, Denis Smith, Christelle De La Fouchardière, Thomas Aparicio, Jaafar Bennouna, Jean-Marc Gornet, Marion Jacquin, Franck Bonnetain, Christophe Borg
Format: Article
Language:English
Published: BMC 2017-08-01
Series:BMC Cancer
Subjects:
Anal carcinoma
Advanced
Metastatic
Docetaxel
And chemotherapy
Online Access:http://link.springer.com/article/10.1186/s12885-017-3566-0

Internet

http://link.springer.com/article/10.1186/s12885-017-3566-0

Similar Items